Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial update assessing safety, tolerability and pharmacokinetics of a recombinant anti-EGFR monoclonal antibody in patients with metastatic colorectal c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Recombinant anti-EGFR monoclonal antibody

Snippet

Sponsor: Sinocelltech Ltd. | Conditions: Metastatic Colorectal Cancer | Phase 1 | Status: UNKNOWN